Compare GSK plc (GSK) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Hilton Hotels Corporation Common Stock — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Hilton Hotels Corporation Common Stock trades at $327.15 (market cap $72.76B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Hilton Hotels Corporation Common Stock for 138 Days on average.
| GSK | HLT | |
|---|---|---|
Market Cap | $91.88B | $72.76B |
Volume | 7,730,529 | 1,148,634 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $350.22 |
52-Week Low | $43.24 | $256.96 |
Typical Hold Time | 93 Days | 138 Days |
Enterprise Value | $111.88B | $85.78B |
Dividend Yield | 3.9% | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Hilton Worldwide (HLT) trades at $326.56, up 1.89% with a bullish technical outlook. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth has been steady, reaching $12.04B in 2025, though valuation multiples like P/E of 47.47 appear elevated. Analyst consensus is strongly positive with 57% buy ratings and a $348.11 price target, while institutional investors have been increasing positions.
The outlook remains favorable given Hilton's strong brand positioning and global travel recovery, but risks include high debt levels and sensitivity to economic cycles. With technical indicators bullish and fundamental growth intact, HLT offers growth potential though current valuation requires careful monitoring of earnings delivery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
